Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × pazopanib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 26 Sarcoma 16 Neoplasm Metastasis 12 Carcinoma, Non-Small-Cell Lung 9 Ovarian Neoplasms 8 Breast Neoplasms 8 Recurrence 6 Neoplasms 5 Melanoma 4 Liposarcoma 4 Leiomyosarcoma 4 Glioblastoma 4 Fallopian Tube Neoplasms 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Neuroendocrine Tumors 3 Lung Neoplasms 3 Kidney Neoplasms 3 Hemangiosarcoma 3 Gastrointestinal Stromal Tumors 3 Thyroid Neoplasms 2 Thyroid Carcinoma, Anaplastic 2 Sarcoma, Synovial 2 Sarcoma, Alveolar Soft Part 2 Rhabdomyosarcoma 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Gliosarcoma 2

Interventions

Temozolomide 69 Bevacizumab 40 Radiotherapy 22 Magnetic Resonance Spectroscopy 19 Irinotecan 17 Specimen Handling 10 Carboplatin 10 Carmustine 9 X-Rays 7 Radiation 7 olaparib 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Nuclear Medicine Department, Hospital 6 Nivolumab 6 Everolimus 6 Cyclophosphamide 6 Biopsy 6 trametinib 5 Thalidomide 5 Cisplatin 5 pembrolizumab 4 palbociclib 4 erdafitinib 4 dabrafenib 4 Lomustine 4 Etoposide 4 Drug Therapy 4 Doxorubicin 4 Aminolevulinic Acid 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00350727 2013-04-19

VEG102857

GlaxoSmithKline

Phase 2 Completed

75 enrolled 45 charts

Glioblastoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡